Moylan-Supported Effort to Control Cost of Insulin Becomes Law

DES PLAINES, Ill. – Fighting to keep healthcare affordable for Illinois residents, state Rep. Marty Moylan, D-Des Plaines, is highlighting a new law capping the monthly co-pays for insulin that took effect on Jan. 1.

“During this pandemic, the importance of affordable healthcare is more important than ever, and this new law will keep the cost of life saving medication in check for over one million Illinois residents,” Moylan said. “No one should ever have to risk their health by rationing their medication because they cannot afford it. Illinoisans deserve to have the medical treatment they need readily available.”

The Moylan-backed Senate Bill 667 which recently went into effect caps the monthly co-pays for insulin at $100 and directs the Illinois Department of Insurance to issue a report to the public regarding insulin pricing practices and variables which contribute to the pricing of healthcare plans and subsequently recommend policy to prevent the overpricing of prescription insulin.

The cost of prescription insulin tripled between 2002 and 2013 forcing one in four diabetes patients to ration their supply. The Moylan backed law aims to reign in the rising price for this life saving medicine for the 1.3 million Illinois adults with diabetes.

“Keeping healthcare affordable is one of my top priorities in this new session, and this new law is a step in the right direction, although there is plenty of work to be done,” Moylan said. “I will continue working to rein in the cost of healthcare amid this pandemic so Illinoisans are not forced to compromise their health for financial stability.”

For questions concerning the newly enacted Senate Bill 667, state issues, legislation or district matters, please contact Moylan’s full-time constituent office at 847-635-6821 or email StateRepMoylan@gmail.com .